OBJECTIVE: In this pilot study, we investigated the feasibility of a home-based, remotely guided exercise intervention for patients with gliomas.DESIGN: Pilot randomized controlled trial (RCT) with randomization (2:1) to exercise or control group.SUBJECTS: Patients with stable grade II and III gliomas.INTERVENTION: The six-month intervention included three home-based exercise sessions per week at 60%-85% of maximum heart rate. Participants wore heart rate monitors connected to an online platform to record activities that were monitored weekly by the physiotherapist.MAIN MEASURES: Accrual, attrition, adherence, safety, satisfaction, patient-reported physical activity, VO2 peak (by maximal cardiopulmonary exercise testing) and body mass index (BMI) at baseline and at six-month follow-up.RESULTS: In all, 34 of 136 eligible patients (25%) were randomized to exercise training ( N = 23) or the control group ( N = 11), of whom 19 and 9, respectively, underwent follow-up. Mean adherence to prescribed sessions was 79%. Patients' experiences were positive. There were no adverse events. Compared to the control group, the exercise group showed larger improvements in absolute VO2 peak (+158.9 mL/min; 95% CI: -44.8 to 362.5) and BMI (-0.3 kg/m²; 95% CI: -0.9 to 0.2). The median increase in physical activity was 1489 metabolic equivalent of task (MET) minutes higher in the exercise group. The most reported reasons for non-participation were lack of motivation or time.CONCLUSION: This innovative and intensive home-based exercise intervention was feasible in a small subset of patients with stable gliomas who were interested in exercising. The observed effects suggest that the programme may improve cardiorespiratory fitness. These results support the need for large-scale trials of exercise interventions in brain tumour patients.
DOCUMENT
Undernutrition is a common problem in Dutch older people and may cause increased length of hospitalization, early institutionalization and decreased quality of life. This cross-sectional study aimed to examine the prevalence of nutrition risk among older people living in the community of Woerden.
MULTIFILE
In this pilot study, we investigated the feasibility of a home-based, remotely guided exercise intervention for patients with gliomas. The six-month intervention included three home-based exercise sessions per week at 60%–85% of maximum heart rate. Participants wore heart rate monitors connected to an online platform to record activities that were monitored weekly by the physiotherapist.
DOCUMENT
Er is momenteel een enorme groei op het gebied van consumentenproducten om activiteiten en bewegingen te meten; zowel voor de fitnessindustrie (bv. Fitbit, Jawbone) als in de gaming wereld (bv Kinect, Wii). Bedrijven op het gebied van zorgtechnologie vragen zich af of zij producten en diensten kunnen ontwikkelen op basis van deze technologie. In dit project richten we ons specifiek op de vraag van de bedrijven of met deze producten het valrisico van ouderen kan worden ingeschat. De incidentele metingen in een klinische omgeving kunnen dan worden vervangen door continue metingen in het dagelijks leven. Het onderzoek dat wordt uitgevoerd betreft het bepalen van de nauwkeurigheid, robuustheid en acceptatie van technologie om in realistische omgevingen (hier: woonomgeving en ziekenhuisom-geving) de bewegingskenmerken van ouderen te meten. Het onderzoek wordt ingericht rond de onderzoeksvraag: Hoe kunnen technologieën voor bewegingsregistratie die zich hebben bewezen in een labsetting worden ingezet in de woonomgeving en in het ziekenhuis, ten behoeve van het inschatten van val-risico bij ouderen? Het onderzoek zal worden uitgevoerd in twee parallel lopende cases: valrisico meten in de woon-omgeving en valrisico meten in het ziekenhuis. In beide gevallen wordt een living lab aanpak ge-volgd: de technologische oplossingen van de MKB worden op iteratieve wijze, in de praktijk , be-studeerd en verder ontwikkeld. Ook de inbedding van de technologie in het zorgproces wordt in het onderzoek meegenomen. De kennis die wordt opgedaan zal worden gebruikt door de participerende MKB in nieuwe pro-ducten en diensten. Het onderzoek wordt uitgevoerd door een multidisciplinair team bestaande uit de Hogeschool van Amsterdam (Domein Digitale Media en Creatieve Industrie en Domein Gezond-heid), de Vrije Universiteit (Bewegingswetenschappen), het AMC (Geriatrie), zorgaanbieders Cor-daan en Amsta en de participerende MKB. De resultaten zullen worden gepresenteerd op twee publieke seminars, in vakbladen en op we-tenschappelijke conferenties.
CRISPR/Cas genome engineering unleashed a scientific revolution, but entails socio-ethical dilemmas as genetic changes might affect evolution and objections exist against genetically modified organisms. CRISPR-mediated epigenetic editing offers an alternative to reprogram gene functioning long-term, without changing the genetic sequence. Although preclinical studies indicate effective gene expression modulation, long-term effects are unpredictable. This limited understanding of epigenetics and transcription dynamics hampers straightforward applications and prevents full exploitation of epigenetic editing in biotechnological and health/medical applications.Epi-Guide-Edit will analyse existing and newly-generated screening data to predict long-term responsiveness to epigenetic editing (cancer cells, plant protoplasts). Robust rules to achieve long-term epigenetic reprogramming will be distilled based on i) responsiveness to various epigenetic effector domains targeting selected genes, ii) (epi)genetic/chromatin composition before/after editing, and iii) transcription dynamics. Sustained reprogramming will be examined in complex systems (2/3D fibroblast/immune/cancer co-cultures; tomato plants), providing insights for improving tumor/immune responses, skin care or crop breeding. The iterative optimisations of Epi-Guide-Edit rules to non-genetically reprogram eventually any gene of interest will enable exploitation of gene regulation in diverse biological models addressing major societal challenges.The optimally balanced consortium of (applied) universities, ethical and industrial experts facilitates timely socioeconomic impact. Specifically, the developed knowledge/tools will be shared with a wide-spectrum of students/teachers ensuring training of next-generation professionals. Epi-Guide-Edit will thus result in widely applicable effective epigenetic editing tools, whilst training next-generation scientists, and guiding public acceptance.
Organ-on-a-chip technology holds great promise to revolutionize pharmaceutical drug discovery and development which nowadays is a tremendously expensive and inefficient process. It will enable faster, cheaper, physiologically relevant, and more reliable (standardized) assays for biomedical science and drug testing. In particular, it is anticipated that organ-on-a-chip technology can substantially replace animal drug testing with using the by far better models of true human cells. Despite this great potential and progress in the field, the technology still lacks standardized protocols and robust chip devices, which are absolutely needed for this technology to bring the abovementioned potential to fruition. Of particular interest is heart-on-a-chip for drug and cardiotoxicity screening. There is presently no preclinical test system predicting the most important features of cardiac safety accurately and cost-effectively. The main goal of this project is to fabricate standardized, robust generic heart-on-a-chip demonstrator devices that will be validated and further optimized to generate new physiologically relevant models to study cardiotoxicity in vitro. To achieve this goal various aspects will be considered, including (i) the search for alternative chip materials to replace PDMS, (ii) inner chip surface modification and treatment (chemistry and topology), (iii) achieving 2D/3D cardiomyocyte (long term) cell culture and cellular alignment within the chip device, (iv) the possibility of integrating in-line sensors in the devices and, finally, (v) the overall chip design. The achieved standardized heart-on-a-chip technology will be adopted by pharmaceutical industry. This proposed project offers a unique opportunity for the Netherlands, and Twente in particular, which has relevant expertise, potential, and future perspective in this field as it hosts world-leading companies pioneering various core aspects of the technology that are relevant for organs-on-chips, combined with two world-leading research institutes within the University of Twente.
